Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of two fixed-dose combinations of dapagliflozin + metformin XR in healthy Thai subjects under fed conditions
TCTR20250302010Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dapagliflozin + metformin, dapagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sun Pharma. Primary endpoints: Primary pharmacokinetic bioequivalence for dapagliflozin and Primary pharmacokinetic bioequivalence for metformin. Started Nov 2025; status: completed.
02
Drugs
dapagliflozin + metformindapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20250302010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250302010.